News | Breast Imaging | March 18, 2025

Architectural distortions detected by DBT alone with no ultrasound correlate and nonmalignant results on core needle biopsy

Derek L. Nguyen, MD
Duke University School of Medicine


March 13, 2025  — According to research published in the American Journal of Roentgenology (AJR), imaging surveillance may be a safe alternative to surgical excision for architectural distortions (ADs) detected by digital breast tomosynthesis (DBT) alone with no sonographic correlate showing benign pathology without atypia on core needle biopsy (CNB).

“The malignancy rate was 0% for ADs without atypia, versus 20% for ADs with atypia, on CNB,” explained first author Derek L. Nguyen, MD, from the radiology department at Duke University School of Medicine in Durham, NC.

Dr. Nguyen and colleagues’ AJR accepted manuscript included patients with ADs detected by DBT alone with no ultrasound correlate and nonmalignant results on stereotactic CNB with 12 vacuum-assisted 9-gauge cores from July 1, 2020, to December 31, 2023. ADs detected by DBT alone with no ultrasound correlate showing concordant benign pathology or radial scar without atypia on CNB were recommended to undergo 6-month and 12-month diagnostic imaging follow-up before returning to annual screening, whereas those showing atypia (with or without radial scar) on CNB were recommended to undergo surgical excision; however, patients could electively undergo the alternative management option. Nguyen et al. then assessed malignancy rates, considering ADs to be nonmalignant based on results of repeat CNB, surgical excision, or 12-month diagnostic imaging follow-up.

Ultimately, for ADs detected by DBT alone with no ultrasound correlate and nonmalignant results on CNB obtaining 12 vacuum-assisted 9-gauge samples, malignancy rates were 0% (0/94) in the absence of atypia (with or without radial scar), versus 20% (3/15) in the presence of atypia (with or without radial scar), on CNB.

54-year-old woman undergoing breast cancer screening

ARRS
(a) Craniocaudal (CC) view from screening digital breast tomosynthesis (DBT) mammogram shows architectural distortion (AD) (circle) in upper inner position. AD was not detected by digital mammography (not shown). (b) Spot CC view from subsequent diagnostic DBT mammogram shows persistence of AD (circle). No ultrasound correlate was identified (not shown). Core needle biopsy of AD was performed, yielding radial scar without atypia. (c) Postbiopsy mammogram shows cylinder clip (arrow) in appropriate position. Biopsy result was considered concordant, and patient underwent recommended imaging surveillance. (d) Spot CC view from diagnostic mammogram performed 12 months later shows stable appearance of AD (circle).

 

 


Related Content

News | Women's Health

Dec. 1, 2025 — ScreenPoint Medical has completed a commercial agreement making its Transpara breast-imaging AI portfolio ...

Time December 03, 2025
arrow
News | RSNA 2025

Dec. 2, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, will present 14 studies at RSNA ...

Time December 02, 2025
arrow
News | Women's Health

Dec. 1, 2025 — A study of data from seven outpatient facilities in the New York region found that 20-24% of all the ...

Time December 02, 2025
arrow
News | Artificial Intelligence

Nov. 25, 2025 – Medical imaging AI company Avicenna.AI has announced a strategic partnership with Ferrum, an AI ...

Time November 25, 2025
arrow
News | Ultrasound Imaging

Nov. 12, 2025 — GE HealthCare and DeepHealth, Inc., a wholly owned subsidiary of RadNet, Inc., have announced their ...

Time November 20, 2025
arrow
News | Artificial Intelligence

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...

Time November 07, 2025
arrow
News | RSNA 2025

Nov. 3, 2025 — QT Imaging Holdings has announced that its chief medical officer, Elaine luanow, MD, will host a seminar ...

Time November 04, 2025
arrow
News | Breast Imaging

Oct. 28, 2025 — QT Imaging Holdings, Inc., a medical device company focused on radiation-free imaging technology, has ...

Time October 28, 2025
arrow
News | RSNA 2025

Oct. 7, 2025 – Clairity Inc., a leader in AI-based breast cancer risk prediction, will make five scientific ...

Time October 07, 2025
arrow
News | Mammography | Mayo Clinic

Early detection is key to breast cancer survival. But nearly half of all women in the U.S. have dense breast tissue ...

Time October 03, 2025
arrow
Subscribe Now